AC Immune SA and collaborators including National Institute on Aging, Alzheimer’s Disease Cooperative Study (ADCS) and LuMind Research Down Syndrome Foundation led by USC Keck School of Medicine conducted a clinical trial on an Alzheimer’s vaccine tested on Down syndrome individuals. The study was a prospective multi-center, placebo-controlled, double-blind and randomized dose-escalation study of 2 doses of ACI-24 versus placebo over 24 months with a total of 21 visits.
Interim results are promising reports Swiss sponsor AC Immune. The company’s liposomal therapeutic anti-Abeta vaccine, dubbed ACI-24, is also being evaluated in mild to moderate Alzheimer’s patients in a Phase 2 study. The vaccine’s safety and efficacy were reported during previous preclinical research. In a company press release, they reported during a key opinion leader (KOL) event that ACI-24 vaccine to treat Alzheimer’s disease-like symptoms in participants with Down Syndrome showed positive results.
CEO Andrea Pfeifer commented: “These initial interim Phase Ib data support the continued study of ACI-24 in this trial to treat AD-like symptoms in DS as well as in our ongoing Phase 2 trial in subjects with mild AD. We thank Dr. Skotko and Professor Mobley, leading Key Opinion Leaders, whose participation today highlights the unmet need and the significant opportunity that exists for studying AD-like symptoms in this more homogenous population, which may yield critical information for the potential of DS subjects as well as the broader AD community.”
Michael S. Rafii, USC Keck School of Medicine